arrow
K

Kelly J. Norsworthy

center for drug evaluation and research
H指数:20
被引数:1,891

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p Deletion

急性髓系白血病合并TP53基因突变或17p缺失患者的真实世界结局与治疗模式

2025-12-130
OAAI
Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): US Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

反应率、无事件生存期(EFS)和总生存期在较高风险骨髓增生异常综合征(MDS)中的研究:美国食品药品监督管理局(FDA)试验层面和患者层面的分析

BLOOD
IF23.1
2024-11-051
PRE
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

FDA批准摘要: Ivosidenib用于异柠檬酸脱氢酶-1突变的复发或难治性急性髓系白血病

2019-06-03113
OAAI
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
LEUKEMIA
IF13.4
2017-03-2134
OAAI